SPOTLIGHT: Trial participants lose Amgen suit

Eight people who participated in a trial of Amgen's experimental therapy for Parkinson's have lost their suit aimed at forcing the biotech giant to continue providing them with the drug. A federal judge said that Amgen had the right to terminate the drug trial. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.